Use of a PPAR-delta agonist for treating muscle atrophy
View Patent ↗The present invention provides methods for treating muscle atrophy by administering a PPARδ agonist.
1. A method for reducing disuse-associated muscle atrophy in a subject in need thereof comprising administering to the subject an effective amount of a PPARδ agonist, wherein the PPARδ agonist is (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the disuse-associated muscle atrophy is caused by limb immobilization in the subject.
3. The method of claim 1 , wherein the disuse-associated muscle atrophy is caused by use of a mechanical ventilator by the subject.
4. The method of claim 1 , wherein reducing disuse-associated muscle atrophy comprises reducing the rate of loss of muscle strength in a muscle tissue of the subject relative to a control, wherein the rate of loss of muscle strength comprises a comparison of one or more measurements of muscle strength in the subject to a baseline measurement of muscle strength in the same subject prior to a period of disuse, wherein muscle strength is measured by a muscle strength test.
5. The method of claim 4 , wherein reducing the rate of loss of muscle strength in the subject comprises a return to the subject's baseline measurement of muscle strength faster than the control following a period of disuse.
6. The method of claim 4 , wherein reducing the rate of loss of muscle strength in the subject comprises a return to the subject's baseline measurement of muscle strength following a period of disuse in less than 90% of the time to return to baseline for a control.
7. The method of claim 4 , wherein the loss of muscle strength in the subject is less than the loss of muscle strength relative to the control during a period of disuse.
8. The method of claim 4 , wherein the loss of muscle strength in the subject comprises less than a 10% loss of muscle strength relative to the subject's baseline measurement of muscle strength prior to a period of disuse.
9. The method of claim 1 , wherein reducing disuse-associated muscle atrophy comprises reducing the rate of loss of muscle mass in a muscle tissue of the subject relative to a control, wherein the rate of loss of muscle mass comprises a comparison of one or more measurements of muscle volume in the subject to a baseline measurement of muscle volume in the same subject, wherein muscle volume is measured by the cross-section area of a muscle.
10. The method of claim 9 , wherein reducing the rate of loss of muscle mass in the subject comprises a return to the subject's baseline measurement of muscle mass faster than the control.
11. The method of claim 9 , wherein reducing the rate of loss of muscle mass in the subject comprises a return to the subject's baseline measurement of muscle mass following a period of disuse in less than 90% of the time to return to baseline for a control.
12. The method of claim 9 , wherein the loss of muscle mass in the subject is less than the loss of muscle mass relative to the control.
13. The method of claim 9 , wherein the loss of muscle mass in the subject comprises less than a 10% loss of muscle mass relative to the subject's baseline measurement of muscle mass prior to a period of disuse.
14. The method of claim 1 , wherein reducing disuse-associated muscle atrophy comprises reducing the rate of loss of Type I muscle fibers in a muscle tissue of the subject relative to a control, wherein the rate of loss of Type I muscle fibers comprises a comparison of one or more measurements of Type I muscle fibers in the subject to a baseline measurement of Type I muscle fibers in the same subject.
15. The method of claim 1 , wherein reducing disuse-associated muscle atrophy comprises reducing the rate of decrease in mitochondrial biogenesis in a muscle tissue of the subject relative to a control, wherein the rate of decrease in mitochondrial biogenesis comprises a comparison of one or more measurements of mitochondrial biogenesis in the subject to a baseline measurement of mitochondrial biogenesis in the same subject.
16. The method of claim 1 , wherein the PPARδ agonist is administered to the subject in need thereof before, during, or after a period of disuse, or any combination thereof.
17. The method of claim 1 , wherein the effective amount of the PPARδ agonist is from 0.1 mg/day to 500 mg/day.
18. A method of reducing the period to weaning from a mechanical ventilator comprising administering to a subject a PPARδ agonist compound in an effective amount, wherein the PPARδ agonist compound is (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
19. The method of claim 18 , wherein the subject is suffering from acute respiratory distress syndrome (ARDS).
20. The method of claim 18 , wherein the period to weaning from a mechanical ventilator is reduced by at least 24 hours.